Pennsylvania Health System Adopts Microbot Medical’s LIBERTY Robotic System
Event summary
- A Pennsylvania-based academic center becomes the first in the state to adopt Microbot Medical’s LIBERTY Endovascular Robotic System.
- The system is now operational across seven U.S. states, with multiple hospitals within health systems adopting it.
- Microbot plans to expand its sales territory to the West Coast following a full market release in Q2 2026.
- The company has secured agreements to expand access to federal healthcare systems, including those serving veterans and military populations.
The big picture
Microbot Medical’s expansion into Pennsylvania marks a strategic milestone, reinforcing its presence in the Northeast U.S. The adoption by prestigious academic centers underscores the system’s potential to transform endovascular procedures. With plans to extend its reach to the West Coast and federal healthcare systems, Microbot is positioning itself for broader market penetration, though it must navigate competition from well-entrenched players.
What we're watching
- Geographic Expansion
- The pace at which Microbot Medical can replicate this adoption in other states, particularly on the West Coast.
- Federal Adoption
- Whether the agreements with federal healthcare systems will accelerate broader market acceptance of the LIBERTY System.
- Competitive Dynamics
- How established robotic surgery providers in New York City and Boston may respond to Microbot’s growing footprint.